Cagrilintide.
About Cagrilintide
Cagrilintide is among the compounds studied in metabolic and weight-regulation research. Activates the amylin receptor (calcitonin receptor/RAMP heterodimer complex) in the area postrema and nucleus tractus solitarius, producing satiety signaling, delayed gastric emptying, and reduced food intake — complementary to, but mechanistically distinct from, the GLP-1 pathway.
Research Application
Studied as a standalone weight-regulation tool and, more prominently, as a synergistic combination partner with GLP-1 agonists, with the rationale that activating two independent satiety pathways produces additive effects on body weight and metabolic parameters.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
A growing number of preclinical and clinical studies exist for metabolic peptides, though the volume varies significantly by substance.
- Lau DCW, et al. Lancet. 2021;398(10317):2160–2172. PMID 34798060
- Enebo LB, et al. Lancet. 2021;397(10286):1736–1748. PMID 33894838
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Similar Peptides
Question about Cagrilintide?
We reply personally – via email or Telegram.